Fig. 6: miR-1304 SNP regulates microRNA maturation.
a, b G allele frequencies for miR-1304 SNP, rs2155248, in different race and ethnic groups. Data obtained from 1000 genomes. c Genotypes checked by sequencing of PCR product for each cell line for rs2155248. d Power analyses showing minimum requirement of sample size at power of 0.8 and p of 0.05. e Representative sequencing data shown for each genotype by PCR product sequencing. f Genotype distribution in 10 African American and 10 Caucasian Americans patient samples were compared. Chi-square analyses confirmed that the allele frequencies at the locus was significantly different between African Americans and Caucasian Americans. p = 0.0034. g The Taqman assay showing relative expression of miR-1304-3p in African Americans (GG/GT) (N = 25), African Americans (TT) (N= 15) and Caucasian Americans (TT) (N = 10) tumor tissues. One Way ANOVA was performed, African Americans (TT) vs African Americans (GG/GT): p =0.0029, Caucasian Americans (TT) vs African Americans (GG/GT): p = 0.008. h MDAMB231 cells were transiently infected with either control vector or miR-1304-TT or miR-1304-GG, and RNAs were extracted. Relative expression of miR-1304-3p were determined by the Taqman assay. AmpR was used as a control to normalize transduction efficiency (N = 3). One way ANOVA was performed, Ctr vs TT: p=0.0003, Ctr vs GG, p < 0.0001, TT vs GG, p < 0.0001. n = 0.5 x 106 cells examined over 3 independent experiments. i Kaplan-Meier analysis was conducted to assess the effect of rs2155248 genotype on overall survival in African American patients. N=25 for GG/GT, N = 15 for TT. Gehan-Breslow-Wilcoxon test was performed and p = 0.0472. j Kaplan-Meier analysis were conducted to assess the effect of miR-1304-3p expression on overall survival in African American patients. N = 20 each. Gehan-Breslow-Wilcoxon test was performed and p = 0.0442. k Proposed model for miR-1304-3p in disparity in outcomes of breast cancer and cancer-adipocyte interaction. Data are presented as mean values +/- SEM.
